Summary
Global Markets Direct’s, ‘Panacea Biotec Limited - Product Pipeline Review - 2016’, provides an overview of the Panacea Biotec Limited’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Panacea Biotec Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Panacea Biotec Limited
- The report provides overview of Panacea Biotec Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Panacea Biotec Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Panacea Biotec Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Panacea Biotec Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Panacea Biotec Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Panacea Biotec Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Panacea Biotec Limited Snapshot 7
Panacea Biotec Limited Overview 7
Key Information 7
Key Facts 7
Panacea Biotec Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Panacea Biotec Limited - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Panacea Biotec Limited - Pipeline Products Glance 15
Panacea Biotec Limited - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Panacea Biotec Limited - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Panacea Biotec Limited - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Panacea Biotec Limited - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Panacea Biotec Limited - Drug Profiles 21
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
polio [strain Sabin] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Nucovac 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
bevacizumab biosimilar 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
cetuximab biosimilar 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
darbepoetin alfa 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
etanercept biosimilar 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
hepatitis B vaccine 2 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibodies for Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
omalizumab biosimilar 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
rituximab biosimilar 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Synthetic Peptide for Alopecia 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
trastuzumab biosimilar 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dengue (tetravalent) vaccine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
influenza vaccine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Japanese encephalitis vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
meningococcal vaccine 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
pertussis (acellular) vaccine 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pneumococcal vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
respiratory syncytial virus vaccine 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Synthetic Peptides to Agonize GLP-1 for Type 2 Diabetes 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
yellow fever vaccine 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Recombinant Protein for Autoimmune Disorders 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Recombinant Protein for Renal Anemia 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Panacea Biotec Limited - Pipeline Analysis 46
Panacea Biotec Limited - Pipeline Products by Target 46
Panacea Biotec Limited - Pipeline Products by Route of Administration 47
Panacea Biotec Limited - Pipeline Products by Molecule Type 48
Panacea Biotec Limited - Pipeline Products by Mechanism of Action 49
Panacea Biotec Limited - Recent Pipeline Updates 50
Panacea Biotec Limited - Dormant Projects 51
Panacea Biotec Limited - Company Statement 52
Panacea Biotec Limited - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List of Tables
Panacea Biotec Limited, Key Information 7
Panacea Biotec Limited, Key Facts 7
Panacea Biotec Limited - Pipeline by Indication, 2016 9
Panacea Biotec Limited - Pipeline by Stage of Development, 2016 12
Panacea Biotec Limited - Monotherapy Products in Pipeline, 2016 13
Panacea Biotec Limited - Combination Treatment Modalities in Pipeline, 2016 14
Panacea Biotec Limited - Phase III, 2016 15
Panacea Biotec Limited - Phase II, 2016 16
Panacea Biotec Limited - Phase I, 2016 17
Panacea Biotec Limited - Preclinical, 2016 18
Panacea Biotec Limited - Discovery, 2016 19
Panacea Biotec Limited - Unknown, 2016 20
Panacea Biotec Limited - Pipeline by Target, 2016 46
Panacea Biotec Limited - Pipeline by Route of Administration, 2016 47
Panacea Biotec Limited - Pipeline by Molecule Type, 2016 48
Panacea Biotec Limited - Pipeline Products by Mechanism of Action, 2016 49
Panacea Biotec Limited - Recent Pipeline Updates, 2016 50
Panacea Biotec Limited - Dormant Developmental Projects,2016 51
Panacea Biotec Limited, Other Locations 53
Panacea Biotec Limited, Subsidiaries 53
List of Figures
Panacea Biotec Limited - Pipeline by Top 10 Indication, 2016 9
Panacea Biotec Limited - Pipeline by Stage of Development, 2016 12
Panacea Biotec Limited - Monotherapy Products in Pipeline, 2016 13
Panacea Biotec Limited - Pipeline by Top 10 Target, 2016 46
Panacea Biotec Limited - Pipeline by Route of Administration, 2016 47
Panacea Biotec Limited - Pipeline by Top 10 Molecule Type, 2016 48
Panacea Biotec Limited - Pipeline Products by Mechanism of Action, 2016 49
